Announcement

Tongshang Hong Kong represented Anqing Shengtang Investment Holdings Group Co., Ltd. (安庆盛唐投资控股集团有限公司) on its issuance of RMB 440 million 3.43 per cent. credit enhanced bonds due 2026 with the benefit of an irrevocable standby letter of credit issued by Industrial and Commercial Bank of China Limited, Anhui Provincial Branch and listed on the Chongwa (Macao) Financial Asset Exchange Co., Ltd. (Bond code: MOXTB2322). This is the first ever credit enhanced bonds issued in Anqing City.

Anqing Shengtang Investment Holdings Group Co., Ltd. holds a diverse business portfolio, including, among others, infrastructure construction business, leasing business, warehousing and loading/unloading business and trading business. ICBC International Securities Limited and Guoyuan Securities Brokerage (Hong Kong) acted as joint global coordinators, joint lead managers and joint bookrunners in this transaction.

Tongshang Hong Kong team was led by Managing Partner, Eric Chow, and Partner, Priscilla Lee, supported by Registered Foreign Lawyer, Kevin Tian, Associate, Kathleen Liu, Trainee Solicitor, Sofia Long and Legal Assistant, Ziwei Qiu.

Tongshang Hong Kong continues to strengthen our notable corporate finance offering with the appointment of Terence Lau as our Senior Consultant. Terence is one of the market-leading corporate finance experts with over 27 years of extensive experience in corporate finance, with a focus on equity offerings, IPOs, M&As and share buy-backs. Terence previously spent more than 15 years as a Partner in two leading international law firms.

Terence has been widely recognised for his exceptional work and outstanding achievements in the legal industry. He is consistently ranked as a “Leading Individual” in the equity capital markets of China and Hong Kong by well-known publications.

"Terence's appointment is a significant milestone for our firm, and it demonstrates our commitment to delivering high-quality legal services to our clients.," said Tongshang Hong Kong's Managing Partner, Eric Chow.

Terence's appointment reinforces our position as a leading corporate finance law firm in the region. As a China-Appointed Attesting Officer, Terence brings a unique perspective and skillset to the firm, further strengthening our capabilities.

On 8 May 2023, Eric Chow & Co. in Association with Commerce & Finance Law Offices (“Tongshang Hong Kong”), together with our PRC office, Commerce & Finance Law Offices (“Tongshang”), jointly represented Beijing Luzhu Biotechnology Co., Ltd. (“Luzhu Biotech”, Stock Code: 02480.HK) in its listing and global offering of H shares on the Main Board of the Hong Kong Stock Exchange, with a market capitlisation of more than HK$6.6 billion at the time of listing. This transaction marks the first initial public offering under Chapter 18A of the Hong Kong Listing Rules in 2023.

Luzhu Biotech is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases.

Luzhu Biotech’s listing is yet another project completed by the collaboration between Tongshang and Tongshang Hong Kong acting as the issuer’s PRC and Hong Kong legal advisers, respectively, where we proudly provided “one-stop shop” comprehensive and high quality PRC and Hong Kong legal services.

Tongshang Hong Kong team was led by Managing Partner Eric Chow, Partners Clement Jiang and Brandon Chow. Other team members include Senior Associate Winnie Tang, Associates Lawrence Tam and Angela Ng, and supported by Legal Assistant Yunsi Xie.

Eric Chow & Co. in Association with Commerce & Finance Law Offices (“TSHK”) recently represented Immunotech Biopharm Ltd (HKEx: 6978) (the “Company”) on its issuance of RMB300 million of convertible bonds under specific mandate, bearing an interest rate of 6% per annum and a maturity date of 3 years from the date of issuance (the “Convertible Bonds”). Subject to the adjustment events, the conversion price of the Convertible Bonds initially was HK$4.81 per conversion share.

TSHK represented the company in its listing on the Main Board of the Hong Kong Stock Exchange back in 2020. We have been their annual retained counsel since its listing. Immunotech Biopharm is a pre-revenue biotechnology company and is currently focusing on the research, development and commercialisation of T cell immunotherapy.

TSHK provided comprehensive legal services to Immunotech Biopharm Ltd throughout this transaction, including the drafting and reviewing of announcements and circular of the Company, comply with all the requirements under the Hong Kong Listing Rules, negotiation and liaison with the regulatory authorities.

TSHK team was led by Managing Partner Eric Chow, Partner Clement Jiang and Partner Brandon Chow, supported by Associate Carol Chan.